SPRB

Spruce Biosciences, Inc.

• NASDAQ·5d ago

  Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade

• TipRanks·03/27 15:36

  Biotech Alert: Searches spiking for these stocks today

• NASDAQ·03/25 16:07

  Wednesday Sector Leaders: Biotechnology, Precious Metals

• TipRanks·03/20 21:33

  Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline

• Benzinga·03/20 21:26

  Spruce Biosciences Says On March 16, Entered Termination Agreement With Kaken Pharmaceutical; Collaboration Agreement With Kaken Pharmaceutical To Terminate Effective March 31, 2026; All Licenses & Rights Granted By Co To Kaken To Be Terminated; No Unearned Milestone Payments Or Royalties

• Reuters·03/20 21:08

  SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING

• Reuters·03/20 21:08

  SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES

• Reuters·03/20 21:05

  Spruce Biosciences FY2025 R&D expenses fell 57.97% to USD 19.5 million, net loss was USD 39 million

• TipRanks·03/12 16:00

  Biotech Alert: Searches spiking for these stocks today

• Dow Jones·03/10 12:53

  Spruce Biosciences Is Maintained at Market Outperform by Citizens

• Dow Jones·03/10 12:53

  Spruce Biosciences Price Target Cut to $170.00/Share From $180.00 by Citizens

• Benzinga·03/10 12:43

  Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $170

• TipRanks·03/10 12:35

  Oppenheimer Remains a Buy on Spruce Biosciences (SPRB)

• Dow Jones·03/10 11:29

  Spruce Biosciences Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

• Benzinga·03/10 11:20

  HC Wainwright & Co. Reiterates Buy on Spruce Biosciences, Maintains $200 Price Target